Cheng-Pang Hsu

发表

Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

Arijit Chakravarty, Tycho Heimbach, Edgar Schuck, 2014, The AAPS Journal.

FLT3 and CDK4/6 inhibitors: Signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia

Yu-Nien Sun, Cheng-Pang Hsu, Yaping Zhang, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.

E. Smit, J. Soria, D. Khayat, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Omecamtiv mecarbil does not prolong QTc intervals at therapeutic concentrations

Cheng-Pang Hsu, B. Darpo, S. Dutta, 2021, British journal of clinical pharmacology.

Measurement of conatumumab‐induced apoptotic activity in tumors by fine needle aspirate sampling

Connie Y. C. Ma, R. Herbst, Cheng-Pang Hsu, 2010, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects

Cheng-Pang Hsu, S. Dutta, Hanze Zhang, 2021, Clinical pharmacology in drug development.

A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects

Cheng-Pang Hsu, Xuening Li, J. Rana, 2019, Clinical pharmacology : advances and applications.

A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

R. Ramlau, J. V. van Meerbeeck, L. Paz-Ares, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

L. Lipton, H. Hurwitz, L. Rosen, 2013, BMC Cancer.

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

L. Saltz, F. Galimi, V. Haddad, 2013, Cancer.

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors

R. Herbst, P. LoRusso, R. Kurzrock, 2010, Clinical Cancer Research.

Title The effect of different dosing regimens of motesanib on the gallbladder : a randomized phase 1 b study in patients with advanced solid tumors Permalink

L. Lipton, H. Hurwitz, L. Rosen, 2013 .

Overexpression of Human Intestinal Oligopeptide Transporter in Mammalian Cells via Adenoviral Transduction

G. Amidon, H. Merkle, Cheng-Pang Hsu, 1998, Pharmaceutical Research.

Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper

A. Kamath, Cheng-Pang Hsu, Hongbin Yu, 2022, mAbs.

Beta Cyclodextrins Enhance Adenoviral-Mediated Gene Delivery to the Intestine

Maria A. Croyle, Blake J. Roessler, Cheng-Pang Hsu, 1998, Pharmaceutical Research.

Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab

Yu-Nien Sun, Cheng-Pang Hsu, Yan Xin, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

FLT3 and CDK4/6 inhibitors: Signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia

Yu‐Nien Sun, Cheng-Pang Hsu, Yilong Zhang, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab

J. Baselga, J. Tabernero, F. Galimi, 2015, Targeted Oncology.

Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies

D. Salinger, C. Endres, E. Hurh, 2011, Clinical pharmacokinetics.

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma

J. Nemunaitis, John W Walker, Cheng-Pang Hsu, 2019, EBioMedicine.

Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab

Cheng-Pang Hsu, G. Block, Yessenia Bartley, 2022, Journal of clinical pharmacology.

Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer

H. Hurwitz, D. Goldstein, H. Burris, 2015, Cancer Chemotherapy and Pharmacology.

Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

Jerome T. Mettetal, J. Mettetal, T. Maurer, 2015, The AAPS Journal.

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

L. Lipton, H. Hurwitz, L. Rosen, 2013, BMC Cancer.

Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab

Yu‐Nien Sun, Cheng-Pang Hsu, Y. Xin, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Use of Classification Regression Tree in Predicting Oral Absorption in Humans

Gordon M. Crippen, Lan Jiang, Volker Fischer, 2004, J. Chem. Inf. Model..

Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.

Jerome T. Mettetal, J. Mettetal, Patrick E. Trapa, 2017, Drug discovery today.

Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing‐off of erenumab within monthly treatment cycle

D. Dodick, Cheng-Pang Hsu, A. Blumenfeld, 2022, Headache.

Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions

Cheng-Pang Hsu, D. Mytych, Cheng Peng, 2022, Cephalalgia : an international journal of headache.

Function and immunolocalization of overexpressed human intestinal H+/peptide cotransporter in adenovirus-transduced Caco-2 cells

G. Amidon, H. Merkle, B. Rothen‐Rutishauser, 1999, AAPS PharmSci.

Optimizing Caco-2 cell monolayers to increase throughput in drug intestinal absorption analysis.

Cheng-Pang Hsu, M. Markowska, A. Streeter, 2001, Journal of pharmacological and toxicological methods.